P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS

• V. Gupta,
• J. Mascarenhas,
• M. Kremyanskaya,
• R. K. Rampal,
• M. Talpaz,
• J.-J. Kiladjian,
• A. Vannucchi,
• S. Verstovsek,
• G. Colak,
• D. Dey,
• C. Harrison

Affiliations

V. Gupta

1 Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada

J. Mascarenhas

2 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

M. Kremyanskaya

2 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

R. K. Rampal

3 Memorial Sloan Kettering Cancer Center, New York, NY

M. Talpaz

4 University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, United States of America

J.-J. Kiladjian

5 Hôpital Saint-Louis, Université de Paris, Paris, France

A. Vannucchi

6 Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy

S. Verstovsek

7 University of Texas MD Anderson Cancer Center, Houston, TX

G. Colak

8 Constellation Pharmaceuticals a MorphoSys Company, Boston, MA, United States of America

D. Dey

9 MorphoSys AG, Planegg, Germany

C. Harrison

10 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom